Best practice in the management of behavioural and psychological symptoms of dementia

Olivier Pierre Tible, Florian Riese, Egemen Savaskan, Armin von Gunten, Olivier Pierre Tible, Florian Riese, Egemen Savaskan, Armin von Gunten

Abstract

Behavioural and psychological symptoms of dementia (BPSD) occur in most patients with dementia. They cause great suffering in patients and caregivers, sometimes more so than the cognitive and functional decline inherent to dementia. The clinical features of BPSD include a wide variety of affective, psychotic and behavioural symptoms and signs. The causes and risk factors for BPSD are multiple and include biological, psychological and environmental variables. Frequently, their combination, rather than any specific factor, explains the occurrence of BPSD in an individual patient. Thus, a sound etiopathogenetic investigation including the patient and the family or care team is essential. The aim is to develop an individualized treatment plan using a therapeutic decision tree modified by the individual and environmental risk profile. Still, treatment may be difficult and challenging. Clinical empiricism often steps in where evidence from controlled studies is lacking. Psychosocial treatment approaches are pivotal for successful treatment of BPSD. Often a combination of different non-pharmacological approaches precedes drug treatment (most of which is off-label). Regular assessments of the treatment plan and any prescriptions must be carried out to detect signs of relapse and to stop any medicines that may have become inappropriate. Even with optimal management, BPSD will not disappear completely in some cases and will remain challenging for all involved parties. This article is a narrative review based closely on the interprofessional Swiss recommendations for the treatment of BPSD. To establish the recommendations, a thorough research of the literature has been carried out. Evidence-based data were provided through searches of Medline, Embase, ISI and Cochrane-Database research. Evidence categories of the World Federation of Biological Societies were used. Additionally, the clinical experience of Swiss medical experts was considered.

Keywords: BPSD; attachment; environmental factors; etiopathogenetic; individualized treatment; personality.

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
Simplified etiopathogenetic model of BPSD. m, modifiable; pm, potentially modifiable; u, unmodifiable.
Figure 2.
Figure 2.
BPSD-DATE interventional algorithm.

References

    1. International Psychogeriatric Association. The IPA complete guides to behavioral and psychological symptoms of dementia. Milwaukee, WI: International Psychogeriatric Association, 2010, (accessed 30 September 2010).
    1. Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2008; 23: 170–177.
    1. Devshi R, Shaw S, Elliott-King J, et al. Prevalence of behavioural and psychological symptoms of dementia in individuals with learning disabilities. Diagnostic 2015; 5: 564–576.
    1. Kales HC, Gitlin LN, Lyketsos CG. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. Similar to DICE (diagnose, investigate, create, evaluate). J Am Geriatr Soc 2014; 62: 762–769.
    1. Perez Romero A, Gonzalez Garrido S. The importance of behavioral and psychological symptoms in Alzheimer’s disease. Neurologia. DOI: 10.1016/j.nrl.2016.02.024.
    1. Savaskan E, Bopp-Kistler I, Buerge M, et al. Therapy guidelines for the behavioural and psychological symptoms of dementia. Praxis 2014; 103: 135–148.
    1. Canevelli M, Adali N, Cantet C, et al. Impact of behavioral subsyndromes on cognitive decline in Alzheimer’s disease: data from the ICTUS study. J Neurol 2013; 260: 1859–1865.
    1. Feast A, Moniz-Cook E, Stoner C, et al. A systematic review of the relationship between behavioral and psychological symptoms (BPSD) and caregiver well-being. Int Psychogeriatr 2016; 28: 1761–1774.
    1. Nourhashémi F, Andrieu S, Sastres N, et al. Descriptive analysis of emergency hospital admissions of patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2001; 15: 21–25.
    1. Toot S, Swinson T, Devine M, et al. Causes of nursing home placement for older people with dementia: a systematic review and meta-analysis. Int Psychogeriatr 2016; 3: 1–14.
    1. Yafee K, Fox P, Newcomer R, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 2002; 287: 2090–2097.
    1. Beeri MS, Werner P, Davidson M, et al. The cost of BPSD in community dwelling Alzheimer’s disease patients. Int J Geriatr Psychiatry 2002; 17: 403–408.
    1. Kraft E, Marti M, Werner S, et al. Cost of dementia in Switzerland. Swiss Med Wkly 2010; 140: w13093.
    1. Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ 2015; 350: h369.
    1. Gitlin LN, Marx KA, Stanley IH, et al. Assessing neuropsychiatric symptoms in people with dementia: a systematic review of measures. Int Psychogeriatr 2014; 26: 1805–1848.
    1. Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 2014; 44: 2308–2314.
    1. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry 1987; 48(Suppl.): 9–15.
    1. Jeon YH, Sansoni J, Low LF, et al. Recommended measures for the assessment of behavioral disturbances associated with dementia. Am J Geriatr Psychiatry 2011; 19: 403–415.
    1. Aalten A, Verhey FR, Boziki M, et al. Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II. Dement Geriatr Cogn Disord 2008; 25: 1–8.
    1. Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the Cardiovascular Health Study. JAMA 2002; 288: 1475–1483.
    1. Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer’s disease. Neurology 1996; 46: 130–135.
    1. Van der Linde RM, Dening T, Stephan BCM, et al. Longitudinal course of behavioural and psychological symptoms of dementia: systematic review. Br J Psychiatry 2016; 209: 366–377.
    1. Elflein HM, Rudy M, Lorenz K, et al. Charles Bonnet’s syndrome: not only a condition of the elderly. Graefes Arch Clin Exp Ophthalmol 2016; 254: 1637–1642.
    1. Cummings J, Mintzer J, Brodaty H, et al. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr 2015; 27: 7–17.
    1. Gnanasekaran G. ‘Sundowning’ as a biological phenomenon: current understandings and future directions: an update. Aging Clin Exp Res 2016; 28: 383–392.
    1. Cohen-Mansfield J, Golander H, Ben-Israel J, et al. The meaning of delusions in dementia: a preliminary study. Psychiatry Res 2011; 189: 97–104.
    1. Cipriani G, Danti S, Vedovello M, et al. Understanding delusion in dementia: a review. Geriatr Gerontol Int 2014; 14: 32–39.
    1. Cohen-Mansfield J, Cohen R, Golander H, et al. The impact of psychotic symptoms on the persons with dementia experiencing them. Am J Geriatr Psychiatry 2016; 24: 213–220.
    1. Cipriani G, Vedovello M, Ulivi M, et al. Delusional misidentification syndromes and dementia: a border zone between neurology and psychiatry. Am J Alzheimers Dis Other Demen 2013; 28: 671–678.
    1. Lanctôt KL, Agüera-Ortiz L, Brodaty H, et al. Apathy associated with neurocognitive disorders: recent progress and future directions. Alzheimers Dement 2017; 13: 84–100.
    1. Robert PH, Clairet S, Benoit M, et al. The apathy inventory: assessment of apathy and awareness in Alzheimer’s disease, Parkinson’s disease and mild cognitive impairment. Int J Geriatr Psychiatry 2002; 17: 1099–1105.
    1. Van der Linde RM, Matthews FE, Dening T, et al. Patterns and persistence of behavioural and psychological symptoms in those with cognitive impairment: the importance of apathy. Int J Geriatr Psychiatry. 32(3):306–315. DOI: 10.1002/gps.4464.
    1. Bubu OM, Brannick M, Mortimer J, et al. Sleep, cognitive impairment and Alzheimer’s disease: a systematic review and meta-analysis. Sleep 2017; 40: zsw032.
    1. Ooms S, Ju YE. Treatment of sleep disorders in dementia. Curr Treat Options Neurol 2016; 18: 40.
    1. McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev 2016; 16: CD009178.
    1. Heller J, Brcina N, Dogan I, et al. Brain imaging findings in idiopathic REM sleep behavior disorder (RBD): a systematic review on potential biomarkers for neurodegeneration. Sleep Med Rev. DOI: 10.1016/j.smrv.2016.06.006.
    1. Cagnin A, Fragiacomo F, Camporese G, et al. Sleep–wake profile in dementia with Lewy bodies, Alzheimer’s disease and normal aging. J Alzheimer Dis 2016; 55: 1529–1536.
    1. McCarter SJ, St, Louis EK, Boeve BF. Sleep disturbances in frontotemporal dementia. Curr Neurol Neurosci Rep 2016; 16: 85.
    1. Mitchell AJ. Neuropsychiatry and behavioural neurology explained. Edinburgh: Saunders, 2004, p.536.
    1. Bizdan M, Bidzan L, Pachalska M. Neuropsychiatric symptoms in patients with Alzheimer’s disease with a vascular component. Ann Agric Environ Med 2014; 21: 412–415.
    1. Kazui H, Yoshiyama K, Kanemoto H, et al. Differences of behavioral and psychological symptoms of dementia in disease severity in four major dementias. PLoS One 2016; 11: e0161092.
    1. Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet 2015; 386: 1672–1682.
    1. Clerc MT, Von Gunten A. Frontotemporal lobar degeneration. In: Tanner P. (eds) Dementia: prevalence, risk factors and management strategies. Hauppauge (Headquarters), New York: Nova Science Publishers, 2014, pp.87–114.
    1. Engelborghs S, Vloeberghs E, Le Bastard N, et al. The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. Neurochem Int 2008; 52: 1052–1060.
    1. Von Gunten A, Bouras C, Kövari E, et al. Neural substrates of cognitive and behavioral deficits in atypical Alzheimer’s disease. Brain Res Rev 2006; 51: 176–211.
    1. Huey ED, Lee S, Devanand DP. Brain regions involved in arousal and reward processing are associated with apathy in Alzheimer’s disease and frontotemporal dementia. J Alzheimer Dis 2016; 55: 551–558.
    1. Torso M, Serra L, Giulietti G, et al. Strategic lesions in the anterior thalamic radiation and apathy in early Alzheimer’s disease. PLoS One 2015; 10: e0124998.
    1. Makovac E, Serra L, Spano B, et al. Different patterns of correlation between grey and white matter integrity account for behavioral and psychological symptoms in Alzheimer’s disease. J Alzheimers Dis 2016; 50: 591–604.
    1. Tokuchi R, Hishikawa N, Sato K, et al. Age-dependent cognitive and affective differences in Alzheimer’s and Parkinson’s diseases in relation to MRI findings. J Neurol Sci 2016; 365: 3–8.
    1. Minger SL, Esiri MM, McDonald B, et al. Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 2000; 55: 1460–1467.
    1. Lagarde J, Sarazin M, Chauviré V, et al. Cholinergic changes in aging and Alzheimer disease: an 18F-F-A 85380 exploratory PET study. Alzheimer Dis Assoc Disord. 31(1):8–12. DOI: 10.1097/WAD000000000163.
    1. Herrmann N, Lanctôt KL, Khan LR. The role of norepinephrine in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 2004; 16: 261–276.
    1. David R, Koulibaly M, Benoit M, et al. Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases: a SPECT study with partial volume effect correction. Clin Neurol Neurosurg 2008; 110: 19–24.
    1. Mitchell RA, Herrmann N, Lanctôt KL. The role of dopamine in symptoms and treatment of apathy in Alzheimer’s disease. CNS Neurosci Ther 2011; 17: 411–427.
    1. Gould E. Serotonin and hippocampal neurogenesis. Neuropsychopharmacology 1999; 21(Suppl. 2): 46S–51S.
    1. Poletti S, Locatelli C, Falini A, et al. Adverse childhood experiences associate to reduced glutamate levels in the hippocampus of patients affected by mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 2016; 71: 117–122.
    1. Ribeiro FM, Vieira LB, Pires RG, et al. Metabolic glutamate receptors and neurodegenerative diseases. Pharmacol Res 2016; 115: 179–191.
    1. Maidment ID, Haw C, Stubbs J, et al. Medication errors in older people with mental health problems: a review. Int J Geriatr Psychiatry 2008; 23: 564–573.
    1. Yesavage JA, Noda A, Hernandez B. Circadian clock gene polymorphisms and sleep–wake disturbance in Alzheimer disease. Am J Geriatr Psychiatry 2011; 19: 635–643.
    1. Mulin E, Zeitzer JM, Yesavage J, et al. Relationship between apathy and sleep disturbance in mild and moderate Alzheimer’s disease: an actigraphic study. J Alzheimers Dis 2011; 25: 85–91.
    1. Zheng Z, Wang J, Yi L, et al. Correlation between behavioural and psychological symptoms of Alzheimer type dementia and plasma homocysteine concentration. Biomed Res Int 2014: 383494.
    1. Flirski M, Sobow T, Kloszewska I. Behavioural genetics of Alzheimer’s disease: a comprehensive review. Arch Med Sci 2011; 7: 195–210.
    1. Kolaczkowski M, Marcinkowska M, Bucki A, et al. Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia. Eur J Med Chem 2015; 92: 221–235.
    1. Stefano P, Concetta C, Luigi D, et al. Role of neurodevelopment involved genes in psychiatric comorbidities and modulation of inflammatory processes in Alzheimer’s disease. J Neurol Sci 2016; 370: 162–166.
    1. Tible O. Présentation des équipes mobiles de Psychogériatrie, Brussels, Belgium, 7–9 September 2016. Société de Psychogériatrie de Langue Française, 32ème Congrès de Psychogériatrie de langue française, pp.25–26, (accessed 9 September 2016).
    1. Malara A, De Biase GA, Bettarini F, et al. Pain assessment in elderly with behavioral and psychological symptoms of dementia. J Alzheimers Dis 2016; 50: 1217–1225.
    1. Pocnet C, Rossier J, Antonietti JP, et al. Personality changes in patients with beginning Alzheimer disease. Can J Psychiatry 2011; 56: 408–417.
    1. Pocnet C, Rossier J, Antonietti JP, et al. Personality traits and behavioral and psychological symptoms in patients at an early stage of Alzheimer’s disease. Int J Geriatr Psychiatry 2013; 28: 276–283.
    1. Prior J, Abraham R, Nicholas H, et al. Are premorbid abnormal personality traits associated with behavioural and psychological symptoms in dementia? Int J Geriatr Psychiatry 2016; 31: 1050–1055.
    1. Boyle LL, Lyness JM, Duberstein PR, et al. Trait neuroticism, depression, and cognitive function in older primary care patients. Am J Geriatr Psychiatry 2010; 18: 305–312.
    1. Johansson L, Guo X, Duberstein PR, et al. Midlife personality and risk of Alzheimer disease and distress: a 38-year follow-up. Neurology 2014; 83: 1538–1544.
    1. Von Gunten A, Pocnet C, Rossier J. The impact of personality characteristics on the clinical expression in neurodegenerative disorders: a review. Brain Res Bull 2009; 80: 179–191.
    1. Hirshfeld-Becker DR, Micco J, Henin A, et al. Behavioral inhibition. Depress Anxiety 2008; 25: 357–367.
    1. Schwartz CE, Hirshfeld-Becker DR, Henin A, et al. Behavioral inhibition in childhood predicts smaller hippocampal volume in adolescent offspring of parents with panic disorder. Transl Psychiatry 2015; 21: e605.
    1. Van Rooij SJ, Kennis M, Vink M, et al. Childhood trauma and COMT genotype interact to increase hippocampal activation in resilient individuals. Front Psychiatry 2016; 14: 156.
    1. Bradley JM, Cafferty TP. Attachment among older adults: current issues and directions for future research. Attachment Hum Dev 2001; 3: 200–221.
    1. Browne CJ, Shlosberg E. Attachment theory, ageing and dementia: a review of the literature. Aging Ment Health 2006; 10: 134–142.
    1. Magai C, Cohen CI, Culver C, et al. Relation between premorbid personality and patterns of emotion expression in mid- to late-stage dementia. Int J Geriatr Psychiatry 1997; 12: 1092–1099.
    1. Fujii M, Butler JP, Sasaki H. Emotional function dementia patients. Psychogeriatrics 2014; 14: 202–209.
    1. Feast A, Orrell M, Russell I, et al. The contribution of caregiver psychosocial factors to distress associated with behavioral and psychological symptoms in dementia. Int J Geriatr Psychiatry 2017; 32: 76–85.
    1. Corbett A, Husebo B, Malcangio M, et al. Assessment and treatment of pain in people with dementia. Nat Rev Neurol 2012; 8: 264–274.
    1. Ouslander J, Bartesl S, Beck C, et al. Consensus statement on improving the quality of mental health care in US nursing homes: management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc 2003; 51: 1287–1298.
    1. S3-Leitlinie Demenzen. In: Deutsche Gesellschaft für Neurologie, HRSG; Leitlinien für Diagnostik und Therapie in der Neurologie, (2016, accessed 27 January 2016).
    1. Livingston G, Kelly L, Lewis-Holmes E, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomized controlled trials. Br J Psychiatry 2014; 205: 436–442.
    1. Abraha I, Rimland JM, Trotta FM, et al. Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-On Top series. BMJ Open 2017; 7: 3:e012759.
    1. Livingston G, Johnston K, Katona C, et al. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 2005; 162: 1996–2021.
    1. Hepburn K, Lewis M, Tornatore J, et al. The Savvy Caregiver program: the demonstrated effectiveness of a transportable dementia caregiver programme. J Gerontol Nurs 2007; 33: 30–36.
    1. Copper C, Mukadam N, Katona C, et al. Systematic review of the effectiveness of non-pharmacological interventions to improve quality of life of people with dementia. Int Psychogeriatr 2012; 24: 856–870.
    1. Schoenmakers B, Buntinx F, DeLepeleire J. Supporting the dementia family caregiver: the effect of home care intervention on general well-being. Aging Ment Health 2010; 14: 44–56.
    1. Kolanowski A. An overview of the need-driven dementia-compromised behavior model. J Gerontol Nurs 1999; 25: 7–9.
    1. Kovach CR, Noonan PE, Schlidt AM, et al. The serial trial intervention: an innovative approach to meeting needs of individuals with dementia. J Gerontol Nurs 2006; 32: 18–25.
    1. McMinn B, Draper B. Vocally disruptive behaviour in dementia: development of an evidence based practice guideline. Aging Ment Health 2005; 9: 16–24.
    1. Hajjar RR, Kamel HK. Sexuality in the nursing home, part 1: attitudes and barriers to sexual expression. J Am Med Dir Assoc 2004; 5: 42–47.
    1. Heyn P, Abreu BC, Ottenbacher KJ. The effects of exercise training on elderly patients with cognitive impairment and dementia: a meta-analysis. Arch Phys Med Rehabil 2004; 85: 1694–1704.
    1. Scholey KA, Woods BT. A series of brief cognitive therapy interventions with people experiencing both dementia and depression: a description of techniques and common themes. Clin Psychol Psychiatry 2003; 10: 175–185.
    1. Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry 2012; 169: 946–953.
    1. Sörensen S, Pinquart M, Duberstein P. How effective are interventions with caregivers? An updated meta-analysis. Gerontologist 2002; 42: 356–372.
    1. Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer’s disease: a meta-analysis. JAMA 2003; 289: 210–216.
    1. Howard RJ, Juszczak E, Ballard CG, et al. Donepezil for the treatment of agitation in Alzheimer’s disease. N Engl J Med 2007; 357: 1382–1392.
    1. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008; 23: 537–545.
    1. Wilcock GK, Ballard CG, Cooper JA, et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008; 69: 341–348.
    1. Von Gunten A. Schwabe Symposium on BPSD: prevalence, clinical importance and treatment options. Second Congress of the European Academy of Neurology, 28–31 May 2016, Copenhagen, Denmark, (accessed 31 May 2016).
    1. Fox C, Crugel M, Maidment I, et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomized double-blind placebo controlled trial. PLoS One 2012; 7: e35185.
    1. Ballard C, Thomas A, Gerry S, et al. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer’s disease (MAIN-AD). J Am Med Dir Assoc 2015; 16: 316–322.
    1. Von Gunten A, Schlaefke S, Überla K. Efficacy of Gingko Biloba extract EGb 761® in dementia with behavioural and psychological symptoms: a systematic review. World J Biol Psychiatry 2016; 17: 622–633.
    1. Lyketsos CG, Del Campo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003; 60: 737–746.
    1. Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the citAD randomized clinical trial. JAMA 2014; 311: 682–691.
    1. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 2006; 25: CD003476.
    1. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011; 306: 1359–1369.
    1. Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry 2016; 173: 543–546.
    1. Tariot PN, Schneider L, Katz IR, et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry 2006; 14: 767–776.
    1. Kurlan R, Cummings J, Raman R, et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007; 68: 1356–1363.
    1. Ballard CG, Gauthier S, Cummings JL, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol 2009; 5: 245–255.
    1. Zhou QP, Jung L, Richards KC. The management of sleep and circadian disturbance in patients with dementia. Curr Neurol Neurosci Rep 2012; 12: 193–204.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다